Historique
Auteur N. SINGLETON
Documents disponibles écrits par cet auteur (15)
Ajouter le résultat à votre sélection Affiner la recherche
OEDT = EMCDDA ; L. LANIEL ; M. GANDILHON ; J. E. ADES ; A. CUNNINGHAM ; N. SINGLETON ; R. SEDEFOV ; P. GRIFFITHS | 2018
RapportCaptagon is reported to be a commonly used stimulant in the Middle East. In addition, some recent media reports have linked this drug to perpetrators of terrorist acts in Europe or terrorist groups based in areas of conflict in the Middle East. [...]Nouveauté
T. GROSHKOVA ; A. CUNNINGHAM ; L. ROYUELA ; N. SINGLETON ; T. SAGGERS ; R. SEDEFOV | 2018
Dans International Journal of Drug Policy (Vol.56, June 2018) Article : PériodiqueBackground: The importance of illicit drug price data and making appropriate adjustments for purity has been repeatedly highlighted for understanding illicit drug markets. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) has [...]
OEDT = EMCDDA ; I. GIRAUDON ; A. M. DINES ; N. SINGLETON ; A. NOOR ; P. I. DARGAN ; D. WOOD | 2020
RapportENGLISH: This report presents the latest findings on drug-related hospital emergencies from a network of sentinel hospitals across Europe. Almost 24 000 emergency presentations were recorded at 32 sentinel hospitals over the first 4 years of th[...]Nouveauté
N. SINGLETON ; A. CUNNINGHAM ; T. GROSHKOVA ; L. ROYUELA ; R. SEDEFOV | 2018
Dans International Journal of Drug Policy (Vol.56, June 2018) Article : PériodiqueInterventions to tackle the supply of drugs are seen as standard components of illicit drug policies. Therefore drug market-related administrative data, such as seizures, price, purity and drug-related offending, are used in most countries for p[...]
A. BOYS ; M. FARRELL ; P. BEBBINGTON ; BRUGHA T. ; COID J. ; R. JENKINS ; G. LEWIS ; J. MARSDEN ; MELTZER H. ; N. SINGLETON ; C. TAYLOR | 2002
PériodiqueFRANÇAIS : En Angleterre et au Pays de Galle, 3142 prisonniers ont été soumis à une enquête par questionnaire concernant leurs caractéristiques démographiques, leur trajectoire sociale, leurs problèmes psychiatriques et leurs consommations de d[...]
This manual provides a step-by-step guide for those involved in planning and managing infectious diseases and drug services, focusing on how to identify barriers to and opportunities for improving provision of HCV testing and access to treatment[...]
N. SINGLETON, Éditeur scientifique ; R. MURRAY, Éditeur scientifique ; L. TINSLEY, Éditeur scientifique | 2006
RapportHome Office Online Report 16/06 brings together the results of three studies which provide robust updated estimates of the size of the illegal drug use problem, from different perspectives. The new studies build on earlier studies but all contai[...]
OEDT = EMCDDA ; L. VANDAM ; P. BORLE ; L. MONTANARI ; T. SURMONT ; A. PIRONA ; D. HEDRICH ; A. GALLEGOS ; N. SINGLETON ; J. MOUNTENEY ; P. GRIFFITHS | 2018
RapportThis report looks at the use of new psychoactive substances (NPS) in prison settings. This is a rapidly developing phenomenon, but empirical data are currently scarce and patchy. There is growing evidence that NPS are responsible for a large sha[...]
K. SKARUPOVA ; N. SINGLETON ; J. MATIAS ; V. MRAVCIK | 2019
Dans International Journal of Drug Policy (Vol.73, November 2019) Article : PériodiqueBackground: The European Web Survey on Drugs aimed to obtain in-depth data on consumption of cannabis, ecstasy/MDMA, cocaine, and amphetamines in different populations of drug users in 16 European countries. This paper examines test-retest relia[...]
The proliferation of new psychoactive substances, or 'legal highs', in recent years has thrown the existing regulatory measures for drugs into sharp relief. As quickly as policy makers seek to control new substances through the Misuse of Drugs A[...]
J. MATIAS ; E. KALAMARA ; F. MATHIS ; K. SKARUPOVA ; A. NOOR ; N. SINGLETON | 2019
Dans International Journal of Drug Policy (Vol.73, November 2019) Article : PériodiqueBackground: Most comparative drug policy analyses utilise measures of drug use, often from general population surveys (GPS). However, the limitations of GPS are well-recognised, including the small numbers of people who use illicit drugs sampled[...]
This paper describes open-source information monitoring and how we use it at the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) in the area of drug markets - what it is and, importantly, what it is not; the methodology for its [...]
N. SINGLETON ; A. CUNNINGHAM ; T. GROSHKOVA ; L. ROYUELA ; R. SEDEFOV ; P. GRIFFITHS | 2023
ChapitreInterventions to tackle the supply of drugs, are seen as standard components of illicit drug policies and drug market-related administrative data, such as seizures, price, purity and drug-related offending, are widely used for policy monitoring [...]![What would an evidence based drug policy be like? [Editorial]](https://bdoc.ofdt.fr/thumbnail.php?type=1&id=76105)
N. SINGLETON ; J. STRANG | 2014
Dans British Medical Journal (Vol.349, n°7987, 13 December 2014) Article : PériodiquePolicy must move beyond evidence based to evidence infused to produce public good. In their foreword to the UK Home Office's comparison of drug policies in various countries, government ministers stated that "the UK will continue to advocate a [...]![Will the current COVID-19 pandemic impact on long-term cannabis buying practices? [Commentary]](https://bdoc.ofdt.fr/thumbnail.php?type=1&id=83230)
T. GROSHKOVA ; T. STOIAN ; A. CUNNINGHAM ; P. GRIFFITHS ; N. SINGLETON ; R. SEDEFOV | 2020
Dans Journal of Addiction Medicine (Vol.14, n°4, July-August 2020) Article : PériodiqueThe COVID-19 pandemic and the response to have resulted in an increase in sales activity levels on darknet markets during the first 3 months of 2020, mainly related to cannabis products. One key question is whether more people will become used t[...]
